Search Results for "Hydrocodone Bitartrate 7 5 Mg"
Privately held US drugmaker Purdue Pharma has been granted Priority Review designation by the US Food and Drug Administration for its once-daily, single-entity hydrocodone bitartrate tablet.
The US Food and Drug Administration (FDA) has granted priority review designation for US-based Purdue Pharma's hydrocodone bitartrate extended-release tablets for treatment of chronic pain.
Purdue Pharma has been granted priority review designation by the US Food and Drug Administration (FDA) for its hydrocodone bitartrate extended-release tablets for treatment of chronic pain.
Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration seeking authorization to market a once-daily, single-entity hydrocodone bitartrate ...
Purdue and Zogenix report their progress in gaining approval for formulations of single-entity hydrocodone bitartrate that are difficult to misuse or abuse. Medscape Medical News
Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology provi...
Once-daily, extended-release hydrocodone bitartrate provides persistent pain relief in patients with chronic nonmalignant and nonneuropathic pain and also comes with abuse-deterrent properties. Meds...
Matching PubMed Articles
Infantile neuronal ceroid lipofuscinosis is a devastating neurodegenerative lysosomal storage disease caused by mutations in the gene (CLN1 or PPT1) encoding palmitoyl-protein thioesterase-1 (PPT1). W...
To determine the relationship between urine drug testing (UDT) frequency and patient adherence for prescribed buprenorphine, carisoprodol, fentanyl, hydrocodone, methadone, morphine, and oxycodone.